Scemblix (asciminib) Patient Assistance Program
Don’t let the high cost of brand STAMP allosteric BCR-ABL1 inhibitor disrupt your chronic myeloid leukemia treatment. We help eligible patients access Scemblix (asciminib tablets) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Scemblix (asciminib) is FDA-approved for treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP): previously treated with two or more tyrosine kinase inhibitors (TKIs), or with T315I mutation. First-in-class STAMP (specifically targeting the ABL myristoyl pocket) allosteric inhibitor — binds allosteric site distinct from ATP-binding site of standard TKIs.
- Without assistance, Scemblix costs commonly run approximately $18,000+ per month.
- Through AffordMyPrescriptions, qualifying patients can access Scemblix for a flat $69.95 per month.
- Other BCR-ABL TKIs for CML: imatinib (Gleevec — brand and generic; first-generation, first-line historical), dasatinib (Sprycel — brand and generic; second-generation), nilotinib (Tasigna — brand and generic; second-generation), bosutinib (Bosulif — brand; second-generation), ponatinib (Iclusig — brand; third-generation, active against T315I). Scemblix's allosteric mechanism is complementary — active against ATP-site TKI-resistant mutations including T315I. Standard-of-care CML monitoring: BCR-ABL PCR every 3 months, cytogenetics. Leukemia and Lymphoma Society (LLS) resources.
What is Scemblix Prescription Assistance Program?
The Scemblix Patient Assistance Program helps eligible patients access this STAMP allosteric BCR-ABL1 inhibitor at little or no cost when meeting income, insurance, and clinical criteria.
At AffordMyPrescriptions, our Patient Advocates handle the entire Scemblix PAP enrollment for a flat $69.95 per month — so you never face a gap in Scemblix CML therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Scemblix enrollment — so you never face a gap in your chronic myeloid leukemia treatment.
Pharmacy Price Comparison
- Without assistance, Scemblix costs thousands per month at specialty pharmacies. A Patient Assistance Program can offset costs if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Generic dasatinib (alt 2G TKI) | ~$500/mo | Cheap generic 2G TKI alt |
| Specialty pharmacy | ~$18,000/mo | Save substantially |
| Walgreens Specialty | ~$19,000/mo | Save substantially |
| CVS Specialty | ~$20,000/mo | Save substantially |
| 340B-eligible institution | ~$15,000/mo | Save substantially |
| Generic imatinib (alt 1G TKI) | ~$400/mo | Cheap first-line generic alt |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Scemblix — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Scemblix Prescription Program?
The Scemblix Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. CML has transformed from historically fatal to well-controlled disease with TKI therapy. Standard TKIs (imatinib, dasatinib, nilotinib generic) are dramatically cheaper. Scemblix novel allosteric mechanism reserved for resistant/intolerant patients.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Scemblix assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Scemblix is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Scemblix:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $18,000+ per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Scemblix assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Scemblix Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Scemblix:
Scemblix is the first-in-class STAMP (specifically targeting the ABL myristoyl pocket) allosteric BCR-ABL1 inhibitor — binds distinct site from standard TKIs. Active against ATP-site TKI-resistant mutations including T315I. Novel mechanism complementary to standard CML TKI therapy.
How It Works:
Chronic myeloid leukemia (CML) is caused by the Philadelphia chromosome translocation t(9;22) creating the BCR-ABL1 fusion oncogene — constitutively active tyrosine kinase drives leukemia proliferation. Standard TKIs (imatinib, dasatinib, nilotinib, bosutinib, ponatinib) target the ATP-binding site of BCR-ABL. CML has been transformed from historically fatal to well-controlled chronic disease with TKI therapy — some patients even achieve treatment-free remission after prolonged deep molecular response. Resistance to standard TKIs can occur via ATP-binding site mutations (T315I is the classic ‘gatekeeper’ mutation resistant to all standard TKIs except ponatinib). Asciminib binds the myristoyl pocket — an allosteric regulatory site distinct from the ATP-binding site. STAMP mechanism (‘Specifically Targeting the ABL Myristoyl Pocket’). Allosteric inhibition is effective against ATP-site TKI-resistant mutations including T315I. Complementary to standard TKIs — even in combination in some settings.
Form and Use:
Scemblix tablets. 80 mg once daily or 40 mg twice daily (for TKI-experienced without T315I) or 200 mg twice daily (for T315I). Continue as long as clinically beneficial. Standard CML monitoring: BCR-ABL PCR every 3 months, cytogenetics.
Generic Availability:
No generic Scemblix. Other BCR-ABL TKIs (Philadelphia chromosome CML): imatinib (Gleevec — brand and generic; first-generation, first-line historically — significantly cheaper), dasatinib (Sprycel — brand and generic; second-generation), nilotinib (Tasigna — brand and generic; second-generation), bosutinib (Bosulif — brand; second-generation), ponatinib (Iclusig — brand; third-generation, active against T315I). CML monitoring: BCR-ABL PCR every 3 months (International Scale) is standard; deep molecular response (MR4.5) may enable treatment-free remission attempts after sustained deep response. Standard-of-care CML care through hematology/oncology. Leukemia and Lymphoma Society (LLS) resources.
Warnings:
Cytopenias (thrombocytopenia, neutropenia, anemia — monitor CBC), pancreatitis (monitor lipase and clinical symptoms), hypertension, hypersensitivity reactions, cardiovascular effects (arterial thromboembolic events, ischemia), pancreatic toxicity (lipase elevation, pancreatitis), hepatotoxicity (elevated LFTs), embryo-fetal toxicity (contraindicated in pregnancy). Other: musculoskeletal pain, fatigue, headache, upper respiratory infections, elevated pancreatic enzymes. Drug interactions: CYP3A substrate; some CYP3A4 inhibitors increase levels. Coordinate all medications with hematology team.
FAQ (Frequently Asked Questions)
How much does Scemblix cost without insurance?
$18,000+ per month at specialty pharmacies. Generic imatinib $400/month, generic dasatinib $500/month, generic nilotinib similar range — significantly cheaper. Scemblix reserved for TKI-resistant or intolerant CML.
How is Scemblix different from other CML TKIs?
Standard TKIs (imatinib, dasatinib, nilotinib, bosutinib, ponatinib) bind BCR-ABL ATP-binding site. Scemblix (asciminib) binds the allosteric myristoyl pocket — STAMP mechanism (‘Specifically Targeting the ABL Myristoyl Pocket’). Effective against ATP-site TKI-resistant mutations including T315I. Novel complementary mechanism — different resistance profile.
Who should get Scemblix?
Adults with Ph+ CML in chronic phase: (1) previously treated with two or more TKIs (multi-TKI-resistant or intolerant), or (2) with T315I mutation. Not first-line for treatment-naive CML — standard TKIs (imatinib, dasatinib, nilotinib) remain first-line with significant efficacy and lower cost.
What is the T315I mutation?
‘Gatekeeper’ mutation in BCR-ABL kinase domain that disrupts standard TKI binding to the ATP-binding site. Historically limited treatment options — only ponatinib (Iclusig) and Scemblix (asciminib) are active. Scemblix’s allosteric mechanism bypasses T315I. BCR-ABL kinase domain mutation testing informs TKI selection.
How is CML monitored?
BCR-ABL PCR every 3 months on International Scale — quantifies leukemia burden. Cytogenetics for Philadelphia chromosome. Molecular response milestones (BCR-ABL <10% at 3 months, <1% at 12 months, <0.1% deep molecular response) guide therapy. Deep sustained molecular response may enable treatment-free remission attempts in select patients.
Take Control of Your Medication Costs
Novel STAMP allosteric CML therapy overcomes standard TKI resistance. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.